ホーム › 非小細胞肺癌 › サウスカロライナ › Charleston
Charleston、SCにおける非小細胞肺癌の臨床試験
Charlestonとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する16件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Medical University of South Carolina /ID# 273272, Charleston
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- Bon Secours Saint Francis Hospital, Charleston
- Medical University of South Carolina, Charleston
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
被験者募集中第3相
- Medical University of South Carolina-Hollings Cancer Center ( Site 0045), Charleston
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Medical University of South Carolina, Charleston
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
被験者募集中第3相
- Medical University of South Carolina, Charleston
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
被験者募集中第1/2相
- MUSC Hollings Cancer Center, Charleston
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- Medical University of South Carolina, Charleston
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
被験者募集中第3相
- Medical University of South Carolina, Charleston
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
被験者募集中第2相
- Ralph H Johnson VA Medical Center, Charleston
- Medical University of South Carolina, Charleston
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
被験者募集中第2相
- USA03-0, Charleston
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2相
- Ralph H Johnson VA Medical Center, Charleston
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2/3相
- Medical University of South Carolina, Charleston
Phase 2 Study of Fingolimod in Lung Cancers
被験者募集中第2相
- Hollings Cancer Center at Medical University of South Carolina, Charleston
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- Medical University of South Carolina, Charleston
GEMINI-NSCLC: NSCLC Biomarker Study
被験者募集中観察研究
- The Medical University of South Carolina, Charleston
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
被験者募集中第1/2相
- Research Site 123, Charleston
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Charlestonにおける他の研究
- うつ病19件の研究
- 脳卒中18件の研究
- 心不全18件の研究
- 心的外傷後ストレス障害16件の研究
- 心血管疾患15件の研究
- 前立腺がん15件の研究
- がん（全種類）14件の研究
- 頭頸部扁平上皮癌14件の研究
- パーキンソン病13件の研究
- 間質性肺疾患13件の研究
- 乳がん12件の研究
- 肺がん11件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。